Actavis
Trial Pipeline
Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris
NCT02651220
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
NCT02654769
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
NCT02210689
Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers
NCT00864604
A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions
NCT00864279
A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions
NCT00865111
Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects
NCT00864500
Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions
NCT00759759
A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions
NCT00864162
A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions
NCT00865410
A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions
NCT00864019
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions
NCT00865462
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions
NCT00865748
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions
NCT00865072
A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions
NCT00865241
A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions
NCT00864058
What the Pipeline for Actavis Shows
According to the ClinicalTrials.gov registry, Actavis is linked to 16 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 16 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Actavis reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 13 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Actavis is Healthy with 13 linked trials, and 7 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.